
    
      The duration of the study for patients is 32 weeks which includes 4 weeks for screening, 24
      weeks for treatment and 4 weeks for follow-up. An extension of the study is proposed until
      Teriflunomide is commercially available in the country where patient lives.

      The duration of the study for healthy volunteers is 25 weeks which includes only one week for
      screening.
    
  